期刊
GASTROENTEROLOGY
卷 152, 期 6, 页码 1297-1309出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.gastro.2017.02.009
关键词
Liver Failure; Cirrhosis; Liver Disease; Mortality; Fulminant Hepatic Failure; Viral Hepatitis; Chronic Hepatitis B; Guidelines
资金
- National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health
- American Gastroenterological Association Foundation (Sucampo) Association of Subspecialty Professors Designated Research Award in Geriatric Gastroenterology
- T. Franklin Williams Scholarship Award
- [K23-DK090303]
- [R01-DK106419-02]
Hepatitis B reactivation associated with immune-suppressive and biological therapies is emerging to be an important cause of morbidity and mortality in patients with current or prior exposure to hepatitis B virus (HBV) infection. The population at risk for HBV reactivation includes those who either currently are infected with HBV or have had past exposure to HBV. Because curative and eradicative therapy for HBV is not currently available, there is a large reservoir of individuals at risk for HBV reactivation in the general population. HBV reactivation with its potential consequences is particularly a concern when these people are exposed to either cancer chemotherapy, immunosuppressive or biologic therapies for the management of rheumatologic conditions, malignancies, inflammatory bowel disease, dermatologic conditions, or solid-organ or bone marrow transplantation. With the advent of newer and emerging forms of targeted biologic therapies, it has become important to understand the mechanisms whereby certain therapies are more prone to HBV reactivation. This review provides a comprehensive update on the current concepts, risk factors, molecular mechanisms, prevention, and management of hepatitis B reactivation. In addition, we provide recommendations for future research in this area.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据